Explore
Clinical Research on Type 2 Diabetes and Its Complications
0 Ungluers have
Faved this Work
Login to Fave
The huge prevalence of type 2 diabetes is a leading human and economic concern worldwide. The diagnosis code of type 2 diabetes includes multiple clinical phenotypes showing different degrees of obesity, fat distribution patterns, types of dyslipidemia, and characteristics of insulin resistance syndrome. In addition, subjects with type 2 diabetes could develop different clinical trajectories, with age being a critical factor in progression. The chronic complications of type 2 diabetes are a major cause of mortality and disability, and are ranked in the top places in western countries’ scores. The pathophysiological heterogeneity of type 2 diabetes is not captured by the current classifications and guidelines. The potential for diabetes progression and complications developing is different depending on the type 2 diabetes cluster, which is mostly regardless of the degree of glycemic control. However, the impact on quality and life expectancy with the current therapeutic approach is not always the same for every individual. Clinical research is the key to reducing the burden of diabetes. New basic, digital, and clinical approaches are obtaining useful knowledge and designing more individualized interventions to prevent, track, and treat diabetic complications. This Special Issue is a clear reflection of this methodological evolution.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 32 times via unglue.it ebook links.
- 32 - pdf (CC BY) at Unglue.it.
Keywords
- acarbose
- advanced glycation end products
- alpha-glucosidase inhibitors
- ambulatory care
- behaviour change intervention
- blood glucose monitoring
- Body Weight
- bone fragility
- bone quality
- bone structure
- cardiac autonomic neuropathy
- cardiac fibrosis
- cardiovascular complications
- Cardiovascular Disease
- Cardiovascular Diseases
- Chemotaxis
- co-design
- comorbidities
- Comorbidity
- complex intervention
- concomitant drugs
- Continuity of Care
- coronavirus infections
- COVID-19
- CVD
- Depression
- developing country
- diabetes
- diabetes complications
- Diabetes Mellitus
- diabetic nephropathy
- diabetic peripheral neuropathy
- diabetic retinopathy
- diabetic sensorimotor polyneuropathy
- dipeptidyl peptidase-4 inhibitor
- Electrophysiology
- empagliflozin
- end-stage kidney disease
- endothelial cells
- Ethiopia
- Fibrosis
- fracture risk
- gender
- glucagon-like peptide-1 receptor agonist
- glucose transport
- glucose variability
- glycemic control
- HbA1c
- hospitalization
- hyperglycemia
- Hypoglycemia
- hypoglycemic agents
- immunosuppressants
- in-hospital mortality
- Korean National Health Insurance Corporation
- liraglutide
- Machine learning
- medicine
- Meta-analysis
- Microvascular complications
- miglitol
- Monocytes
- n/a
- NAFLD
- NASH
- nephropathy
- non-alcoholic fatty liver disease
- non-alcoholic steatohepatitis
- Obesity
- obesity and diabetes mellitus type 2
- patient participation
- patient profiles
- patient transfer
- pneumatosis intestinalis
- poststroke complications
- prediction
- prednisone
- primary care
- progression
- pulse wave velocity
- random forest
- reactive oxygen species (ROS)
- Readmission
- real-world evidence
- Research
- Risk factors
- screening
- secondary care
- semaglutide
- sex
- SGLT-2
- skin autofluorescence
- stroke outcome
- SURE study
- Telemedicine
- type 2
- type 2 diabetes
- type 2 diabetes mellitus
- urine albumin-creatinine ratio
- vascular dysfunction
- VEGFR-1
- VEGFR-2
- voglibose
Links
DOI: 10.3390/books978-3-0365-9419-4Editions